Initial genome sequencing and analysis of multiple myeloma

Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly understood. Here we report the massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs. Several new and unexpected oncogenic mechanisms were suggested by the pattern of somatic mutation across the data set. These include the mutation of genes involved in protein translation (seen in nearly half of the patients), genes involved in histone methylation, and genes involved in blood coagulation. In addition, a broader than anticipated role of NF-κB signalling was indicated by mutations in 11 members of the NF-κB pathway. Of potential immediate clinical relevance, activating mutations of the kinase BRAF were observed in 4% of patients, suggesting the evaluation of BRAF inhibitors in multiple myeloma clinical trials. These results indicate that cancer genome sequencing of large collections of samples will yield new insights into cancer not anticipated by existing knowledge.

[1]  I. Fidler,et al.  Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. , 1991, Cancer research.

[2]  Mark M. Davis,et al.  Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells , 1994, Cell.

[3]  K. Offit,et al.  Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Dyer,et al.  Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon. , 1996, Blood.

[5]  Liming Yang,et al.  Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. , 2002, Immunity.

[6]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[7]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[8]  John Q Trojanowski,et al.  ‘Unfolding’ pathways in neurodegenerative disease , 2003, Trends in Neurosciences.

[9]  G. Sauvageau,et al.  Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis. , 2003, Experimental hematology.

[10]  K. Calame,et al.  Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. , 2003, Immunity.

[11]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[12]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[13]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[14]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[15]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Regev,et al.  Conservation and evolvability in regulatory networks: the evolution of ribosomal regulation in yeast. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  W. Ruf,et al.  Thrombin generation and the pathogenesis of cancer. , 2006, Seminars in thrombosis and hemostasis.

[19]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[20]  Stefano Monti,et al.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.

[21]  Wei Jiang,et al.  Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering , 2007, BMC Genomics.

[22]  R. Sitia,et al.  Managing and exploiting stress in the antibody factory , 2007, FEBS letters.

[23]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[24]  A. Protopopov,et al.  The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis , 2007, Cancer cell.

[25]  E. Lander,et al.  The Mammalian Epigenome , 2007, Cell.

[26]  D. Tollervey,et al.  The exosome subunit Rrp44 plays a direct role in RNA substrate recognition. , 2007, Molecular cell.

[27]  C. Sander,et al.  Determinants of protein function revealed by combinatorial entropy optimization , 2007, Genome Biology.

[28]  B. Séraphin,et al.  A single subunit, Dis3, is essentially responsible for yeast exosome core activity , 2007, Nature Structural &Molecular Biology.

[29]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[30]  B. Dallapiccola,et al.  Array‐based comparative genomic hybridization in early‐stage mycosis fungoides: Recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF , 2008, Genes, chromosomes & cancer.

[31]  Antony V. Cox,et al.  Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing , 2008, Nature Genetics.

[32]  J. Wilusz,et al.  RNA recognition by 3'-to-5' exonucleases: the substrate perspective. , 2008, Biochimica et biophysica acta.

[33]  T. Jensen,et al.  The exosome: a multipurpose RNA-decay machine. , 2008, Trends in biochemical sciences.

[34]  L. Glimcher,et al.  The endoplasmic reticulum stress response in immunity and autoimmunity , 2008, Nature Reviews Immunology.

[35]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[36]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[37]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[39]  Bin Tean Teh,et al.  Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.

[40]  P. Gómez-Puertas,et al.  Determination of Key Residues for Catalysis and RNA Cleavage Specificity , 2009, The Journal of Biological Chemistry.

[41]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[42]  L. Hendershot,et al.  CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. , 2010, Molecular immunology.

[43]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[44]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[45]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[46]  Govind Bhagat,et al.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. , 2010, Cancer cell.

[47]  N. Munshi,et al.  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo , 2010, British journal of haematology.